*To the Editor*:

The dramatic improvement in prognosis for individuals with cystic fibrosis (CF) must not be overlooked in deliberations about the use of intensive care during the coronavirus disease (COVID-19) pandemic.

Thanks to advances in treatment options and improvements in care, the median predicted survival for people with CF in the United States is approaching 50 years of age and steadily climbing ([@bib1]). With the recently approved combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta), which addresses the basic defect in CF, many people with CF are experiencing transformational improvements in quality of life and lung function that will undoubtedly further increase survival.

For patients with advanced CF lung disease, the outlook has also dramatically improved. Before the U.S. Food and Drug Administration approved Trikafta, the median survival for patients with CF and FEV~1~ \< 30% predicted was shown to be \>6.5 years ([@bib2]). Recent studies reveal improving critical care outcomes, with unanticipated survival and functional recovery from respiratory failure precipitated by influenza and other acute infections. These data prompted the developers of the 2020 Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced CF to recommend that these individuals should be considered eligible for intensive care ([@bib3]).

As states and hospitals turn to emergency triage plans to ensure that scarce medical resources are allocated wisely, we are concerned that some plans use the mere presence of existing health conditions, including CF, as a determining factor in these decisions. This approach fails to recognize that CF has a wide range of disease manifestations. Just as importantly, putting CF in the same category as other chronic lung diseases fails to account for the fact that individuals with CF typically are decades younger and more functional than those with more common chronic lung diseases. Although it is important to give frontline healthcare workers guidance during this crisis, considering all chronic lung diseases as similar, both as a risk factor for higher mortality from COVID-19 pneumonia and as a rationale for denying life-saving intensive care to people with CF, is too simplistic.

Alarmingly, several states have created regional triage plans that reflect an outdated understanding of CF and run the risk of denying care without taking current clinical realities into account. For example, Tennessee includes the presence of CF with FEV~1~ \< 30% as a reason for denying hospital admission ([@bib4]). Although risk stratification is important when allocating resources, the blanket exclusion of individuals with CF and FEV~1~ \< 30% predicted is based on an inaccurate understanding of the current survival outcomes for patients with CF and does not factor in the short- and long-term impacts of disease-modifying CF therapy.

The University of Pittsburgh has proposed an algorithm that looks beyond the presence of an underlying condition with the application of a multiprinciple allocation framework to aid providers in these difficult times ([@bib5]). This algorithm uses a life expectancy of \<5 years, before COVID-19 infection, as an indicator of lower priority for critical care or ventilator use. Individuals with CF and FEV~1~ \< 30% predicted have a predicted median survival of \>5 years, and that rate predates the widespread availability of the transformational therapy Trikafta. Accordingly, individuals with advanced CF lung disease should not have a lower priority for intensive care.

We are in unprecedented times, and healthcare teams may face tremendously difficult decisions related to rationing ventilators and offering intensive care. As states and institutions consider revising existing triage plans or formulating new ones, decision-makers should be careful to avoid language that excludes patients from receiving care because of an underlying condition without carefully considering the prognosis for those individuals. It is vitally important that crisis standards of care factor in accurate, disease-specific prognostic information as patients are triaged.

The following individuals are cosignatories of this letter: Laurie Snyder, M.D., Duke University, Durham, NC; Christian Merlo, M.D., M.P.H., Johns Hopkins University, Baltimore, MD; Erin Lowery, M.D., M.S., Loyola University, Chicago, IL; Jagadish Patil, M.D., University of Minnesota, Minneapolis, MN; Josh Diamond, M.D., University of Pennsylvania, Philadelphia, PA; Matthew Morrell, M.D., University of Pittsburgh, Pittsburgh, PA; Erika Lease, M.D., University of Washington, Seattle, WA; Ramsey Hachem, M.D., Washington University in St. Louis, St. Louis, MO; Luke Benvenuto, M.D., Columbia University, New York City, NY; Isabel Neuringer, M.D., Massachusetts General Hospital, Boston, MA; Gundeep Dhillon, M.D., Stanford University, Palo Alto, CA; S. Samuel Weigt, M.D., University of California Los Angeles, Los Angeles, CA; and Steven Hays, M.D., University of California, San Francisco, San Francisco, CA.

Originally Published in Press as DOI: [10.1164/rccm.202004-0999LE](http://dx.doi.org/10.1164/rccm.202004-0999LE) on April 14, 2020

[**[Author disclosures](http://www.atsjournals.org/doi/suppl/10.1164/rccm.202004-0999LE/suppl_file/disclosures.pdf)**]{.ul} are available with the text of this letter at [www.atsjournals.org](http://www.atsjournals.org).
